MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND
December 05, 2024 18:00 ET | Source: MediciNova, Inc. LA JOLLA, Calif.,…
Xinhua Silk Road: Annual analysis report on taro price index released at the 2024 Boao Forum for Entrepreneurs
BEIJING, Dec. 5, 2024 /PRNewswire/ -- The annual analysis report on the…
Xinhua Silk Road: Annual analysis report on taro price index released at the 2024 Boao Forum for Entrepreneurs
BEIJING, Dec. 5, 2024 /PRNewswire/ -- The annual analysis report on the…
Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban
November 16, 2024 16:38 ET | Source: Anthos Therapeutics Data presented at…
Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban
November 16, 2024 16:38 ET | Source: Anthos Therapeutics Data presented at…
WorldInvest.org Enhances Trading Experience with Expert Analysis Team to Guide Market Decisions
New York, NY, Nov. 11, 2024 (GLOBE NEWSWIRE) -- WorldInvest.org Strengthens Market…